DNA-dependent protein kinase (PRKDC) has been shown to modulate tumor sensitivity to chemotherapy and is a potential prognostic and predictive indicator of the efficacy of adjuvant chemotherapy in cancer patients. The gene discussed is PRKDC; the disease is neoplasm.